The biologics market continues to witness an impressive rate of growth and the monoclonal antibody market, in particular, has contributed remarkably to the expansion of this segment within the pharmaceutical industry. In 2006, close to 80% of the annual biologics growth rate in the United States (US) was attributed to cancer and anti-TNF antibodies, with increases in growth of 56% and 25%, respectively, compared to those in the previous year. Additionally, the monoclonal antibody sector is anticipated to achieve a growth rate of approximately 14% by 2012, easily outstripping the predicted...
The biologics market continues to witness an impressive rate of growth and the monoclonal antibody market, in particular, has contributed remarkably t...
This book examines vital considerations in designing effective translational strategies in the development of antibody-based therapeutics, including the relationship between the `unit dose' and `unit effect' with respect to beneficial and deleterious effects.
This book examines vital considerations in designing effective translational strategies in the development of antibody-based therapeutics, including t...